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Introduction: This pilot study used a prospective longitudinal design to compare the effect of adjuvant whole
breast radiation therapy (WBRT) versus partial breast radiation therapy (PBRT) on fatigue, perceived stress, quality of
life and natural killer cell activity (NKCA) in women receiving radiation after breast cancer surgery.
Methods: Women (N = 30) with early-stage breast cancer received either PBRT, Mammosite brachytherapy at dose
of 34 Gy 10 fractions/5 days, (N = 15) or WBRT, 3-D conformal techniques at dose of 50 Gy +10 Gy Boost/30
fractions, (N = 15). Treatment was determined by the attending oncologist after discussion with the patient and the
choice was based on tumor stage and clinical need. Women were assessed prior to initiation of radiation therapy
and twice after completion of radiation therapy. At each assessment, blood was obtained for determination of
NKCA and the following instruments were administered: Perceived Stress Scale (PSS), Functional Assessment of
Cancer Therapy-Fatigue (FACT-F), and Functional Assessment of Cancer Therapy-General (FACT-G). Hierarchical linear
modeling (HLM) was used to evaluate group differences in initial outcomes and change in outcomes over time.
Results: Fatigue (FACT-F) levels, which were similar prior to radiation therapy, demonstrated a significant difference
in trajectory. Women who received PBRT reported progressively lower fatigue; conversely fatigue worsened over
time for women who received WBRT. No difference in perceived stress was observed between women who
received PBRT or WBRT. Both groups of women reported similar levels of quality of life (FACT-G) prior to initiation
of radiation therapy. However, HLM analysis revealed significant group differences in the trajectory of quality of life,
such that women receiving PBRT exhibited a linear increase in quality of life over time after completion of radiation
therapy; whereas women receiving WBRT showed a decreasing trajectory. NKCA was also similar between therapy
groups but additional post hoc analysis revealed that better quality of life significantly predicted higher NKCA
regardless of therapy.
Conclusions: Compared to WBRT, PBRT results in more rapid recovery from cancer-related fatigue with improved
restoration of quality of life after radiation therapy. Additionally, better quality of life predicts higher NKCA against
tumor targets, emphasizing the importance of fostering quality of life for women undergoing adjuvant radiation
therapy.
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Radiation therapy after surgical removal of an early
breast cancer is a very important part of breast conser-
vation treatment. The classic radiation schedule consists
of a course of whole breast radiation therapy (WBRT)
lasting for 6–6.5 weeks, which targets the entire breast
tissue and underlying structures. An alternative ap-
proach is partial breast radiation therapy (PBRT), using
brachytherapy. This approach targets only the breast tis-
sues around the tumor bed and is administered over a
short-course of five days. Brachytherapy for breast can-
cer is an evolving technique that can simplify radiation
therapy, reduce toxicity, increase patient convenience,
and possibly increase utilization of breast-conserving
approaches to treatment. Results from several phase I
and II studies document that accelerated PBRT using
interstitial catheters has produced excellent 5-year
results with regard to local tumor control, toxicity, and
cosmesis [1-4]. In 2009 the American Society of Radi-
ation Oncology published guidelines and recommenda-
tions for the use of PBRT [5]. However, definitive
outcomes regarding local control and survival await
completion of an ongoing national study comparing
PBRT to WBRT [5,6].
Cancer and its treatment result in behavioral symptom
distress, and one of the most pervasive and distressing
symptoms is fatigue [7]. Cancer-related fatigue is more
intense than typical fatigue and may be due to the dis-
ease itself and/or cancer treatment [8]. Most women
undergoing radiation therapy for breast cancer experi-
ence fatigue [9], which typically subsides within weeks
after completion of radiation therapy [10]. Yet, for some
women, fatigue persists well beyond cancer treatment
[11]. A longitudinal study of women with breast cancer
found that 35% of women reported fatigue 1–5 years
after treatment [12], while 5–10 years later, 34% contin-
ued to experience fatigue [13]. Variation in fatigue tra-
jectories may also be related to dose and field size of
radiation [14], as well as psychological and personal fac-
tors [15]. The human cost of cancer-associated fatigue is
high, as it may lead to interruption of or discontinuation
of cancer treatment [16,17]. Fatigue is also associated
with shorter recurrence-free survival and overall survival
in women with breast cancer [18]. It is clear that fatigue
impairs overall quality of life [8,19,20] and, if chronic, fa-
tigue can increase the need for healthcare services and
result in lost wages [21].
The biological mechanism(s) underlying radiation-
associated fatigue are unclear; however, evolving evi-
dence implicates alterations in immune effector func-
tion, namely increased proinflammatory mediators
[9,22]. Other types of immune dysregulation have also
been associated with cancer treatment, most notably,
reduced natural killer cell activity (NKCA) [23-25].Reduced NKCA may have important long term implica-
tions for cancer patients in that NK cells defend against
tumor metastasis, tumor initiation, and primary tumor
growth [26-29]. Epithelial tumors, such as breast cancer,
are especially susceptible to the anti-tumor effects of NK
cells [27,30-34]. During critical times marked by risk for
tumor dissemination, such as after surgery and during
the early phase after completion of adjuvant radiation
therapy, NK cell mediated anti-tumor defense becomes
particularly important [35-38].
Evidence also suggests that adjuvant breast radiation
may directly alter immune function [39,40]. Given that
WBRT involves radiation of a greater volume of breast
and normal tissues, with tangential fields that includes
the lower axillary nodes, it may produce greater altera-
tions of immune function [41], contributing to greater
fatigue [22]. In contrast, PBRT is a localized treatment
and does not include lymph nodes in the radiation field.
Yet, for PBRT the radiation dose is given rapidly and in
larger fractions, which may have other associated tox-
icity risks [42].
To date, studies comparing WBRT to PBRT have pri-
marily focused on ‘local control’ and ‘cosmesis,’ as
emphasized by the National Surgical Breast and Bowel
Project [5,6]. Few studies have evaluated these two types
of radiation for other outcomes, such as behavioral
symptom distress and quality of life [14,43-45]; while no
studies to our knowledge have compared immune out-
comes, like NKCA. Thus, the purpose of this study was
to compare the effect of adjuvant WBRT versus PBRT
on fatigue, perceived stress, quality of life and NKCA in




This was a non-randomized prospective multi-site pilot
study, fully approved by participating institutional review
boards for the study of human subjects. Treatment was
determined by the oncologist after discussion with the
patient. Choice was based on tumor stage and clinical
need. Participant eligibility criteria for the PBRT group
were as follows: age >45 years; non-lobular histology
and DCIS, pathological stages T1 (lesions ≤ 2 cm),
N0 M0; unilateral breast cancer, negative surgical margins
(> 2 mm) both for the invasive component and the DCIS
component; no extensive intraductal component. For the
WBRT group, to maintain homogeneity, criteria were the
same except that lobular histologies were allowed. All
grades of DCIS were eligible. Common additional exclu-
sion criteria for both groups were as follows. Women
were excluded if they: received chemotherapy, had recur-
rent breast cancer, had major immune-based disease or
dysfunction, were diagnosed with psychoses, were drug
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tics or antidepressant drugs, or drugs known to affect the
immune system.
Procedures
Following breast conserving surgery and prior to initi-
ation of radiation treatment, the purpose and nature of
the study was discussed and eligible women were in-
vited to participate. Women were enrolled from Loyola
University Medical Center and Northwest Community
Hospital. After obtaining informed consent, fatigue, per-
ceived stress, and quality of life were measured by
self-report using established psychometric instruments.
Demographic information and medical history were
obtained by patient interview and medical record review.
Blood was drawn between 9 AM-4 PM by venipuncture
(30 ml) for NKCA and immediately transported to the
research laboratory. Subsequent data collection occurred
in the clinic setting. Outcome variables were measured
prior to the initiation of any radiation therapy and at
two time periods after completion of radiation therapy.
Post radiotherapy time points were anchored with re-
spect to the end of radiation therapy. The second time
point for women in the WBRT group took place upon
completion of the whole breast radiation therapy, ap-
proximately 7 weeks after the initial time point and for
women in the PBRT upon completion of the partial radi-
ation therapy, approximately 6 days after the initial time
point. The third time point was 6 weeks after the T2 for
both groups. The difference in the data collection sche-
dules was accommodated by the statistical approach,
which projected outcomes through 6-weeks after radi-
ation treatment (discussed below).
Radiation techniques
The technique of PBRT using Mammosite has been
described elsewhere [45]. A CT scan was obtained for
brachytherapy planning and verification films were taken
at each fraction. The dose prescribed at 1 cm from the
surface of the balloon was 3400 cGy in ten fractions
twice a day over five days. WBRT was delivered with
3-dimensional conformal techniques with 50 Gy in 25
fractions followed by a 10 Gy lumpectomy bed boost
in 5 fractions. The patients in the two groups were not
directly matched, but demographics were similar due
to the strict eligibility criteria.
Behavioral measures
Functional assessment of cancer therapy – fatigue – (FACT-F)
FACT-F is a 13-item scale used extensively in individuals
with cancer. FACT-F has good test-retest reliability
(0.87) and strong internal consistency (coefficient
alpha = 0.93). Choices for each item on the FACT-F scale
range from 0–4; the range of possible scores is 0–52,with 0 being the worst possible score and 52 the best.
Convergent and discriminant validity testing has previ-
ously demonstrated a significant positive relationship
with other measures of fatigue and a negative correlation
with vigor [46]. Cronbach alpha for our sample was 0.95.
Perceived stress scale (PSS)
The PSS is a 10 item Likert scale that measures global
life stress, by assessing the degree to which experiences
are appraised as uncontrollable and unpredictable [47].
Scores can range from 0 to 40, with higher scores indi-
cating greater level of perceived stress. Reliability (stabil-
ity) is reported as 0.85, with Cronbach alphas ranging
from 0.75-0.86 [48]. Cronbach alpha for our sample was
0.84.
Functional assessment of cancer therapy – general (FACT-G)
FACT-G is a 27-item instrument that measures quality
of life based on four domains: physical well being, so-
cial/family well being, emotional well being, and func-
tional well being. For the purposes of this study, the
analyses only used the total score, representing a com-
posite of quality of life. FACT-G has established relia-
bility, with a Cronbach alpha of 0.92 and a reported
test-retest reliability of 0.93 [46]. The total score range
for FACT-G is from 0 to 108, with higher scores indi-
cating greater general well being. Cronbach alpha for
our sample was 0.94.
Immune measures
Isolation of peripheral blood mononuclear cells
Blood was collected (between 9 AM and 4 PM) in sterile
heparinized tubes and processed immediately. Peripheral
blood was overlaid onto Ficoll/Hypaque and centrifuged
at 1000 x g for 20 min. The peripheral blood mono-
nuclear cells (PBMC) at the interface were washed twice
with Hank's Balanced Salt Solution prior to assessment,
as described previously [49].
Natural killer cell activity (NKCA)
NKCA was determined using a tumor cell cytotoxicity
assay, as previously described [23]. K562 tumor cells,
obtained from the American Type Culture Collection,
Rockville, MD, maintained in vitro in Corning 25 cm2
tissue culture flasks (Corning Glass Works, Corning,
NY) in RPMI 1640 (Gibco Laboratories, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS)
low LPS; (Gibco Laboratories, Grand Island, NY), 100
units/ml penicillin, 100ug/ml streptomycin (Whittaker
M. A. Bioproducts, Walkersville, MD), 0.1 Mm non-
essential amino acids and 2 Mm L-glutamine (Gibco La-
boratories, Grand Island, NY). For the assay K562 cells
were washed once in culture medium, pelleted by centri-
fugation at 500 x g for 10 min and resuspended in
Table 1 Demographic Characteristics of Participants
Based on Type of Radiotherapy
Demographic Variable Mean (SD)/Percent
WBRT PBRT
(n = 15) (n = 15)












Abbreviations: WBRT =whole breast radiation therapy, PBRT = partial breast
radiation therapy.
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of 51Cr (Perkin-Elmer, Warrenville, IL) was added to ap-
proximately 1 x 107 cells in a final volume of 0.2 ml.
The cells were incubated at 37° Celsius with 5% CO2 for
one hour with agitation every 10 min. Subsequently, the
cells were washed four times in HBSS, resuspended to 5
x 105 cells/ml in culture medium and 0.01 ml (5 x 103)
was aliqouted to each well of a 96 well, round bottom
assay plate (Corning Glass Works, Corning, NY).
PBMCs and radiolabeled cells were cultured for four
hours. Following four hours of incubation, the super-
nates were removed using a Skatron harvesting press
(Skatron Inc., Sterling, VA) and the associated radio-
activity was determined using the Cobra II Series Auto
Gamma Counting System by Packard Instrument Com-
pany (Meriden, CT). Maximum release was obtained by
adding 0.05% Novidet P-40 (Sigma Chemical Co., St.
Louis, MO). Results are expressed as % cytotoxicity and
calculated by the formula below:
% Cytotoxicity ¼
experimental DPMð Þ  minimumDPMð Þ100
maximum DPMð Þ  minimum DPMð Þ
DPM ¼ disintegrations per minute
All experimental means were calculated from triplicate
values. Lytic units (LU) were calculated by a program
written by David Coggins (FCRC, Frederick, MD) and
reflect the number of cells per 107 effectors required to
achieve 20% lysis of the targets.
Statistical analysis
Hierarchical linear models (HLM) 6.08 software was used
to compute multilevel model of change [50], based on
full maximum likelihood estimation. This approach was
used to examine intra-individual and inter-individual
differences in baseline and trajectories of change over
time in fatigue, quality of life, perceived stress, and
NKCA. The post radiotherapy time points were anchored
with respect to the end of radiation therapy; women in
the two groups had different data collection schedules
that were accommodated by this statistical approach. Un-
like the traditional analysis of variance for repeated mea-
sures, HLM treats time as a continuous variable letting
each participant have her own data collection schedule
(i.e., dependent on type of radiation therapy).
In HLM with longitudinal data, the outcome variables
(i.e., fatigue, quality of life, perceived stress, and NKCA)
are conceptualized to be nested within individuals and
the growth modeling of change in these variables has
two levels. At Level 1, the outcome variable is a function
of within-person change parameters plus error. At Level
2, outcomes are modeled as a function of predictorvariables that vary between participants (i.e., type of ra-
diation treatment and demographic factors), plus an
error associated with each individual [50].
HLM analysis was conducted separately for each vari-
able (i.e., fatigue, quality of life, perceived stress, and
NKCA) and was performed in two steps. First, potential
group effects of radiation treatment were examined with-
out any other variables in the Level 2 models. In the sec-
ond step, age and use of anti-estrogen endocrine therapy
were added to the models to control for potential con-
founding effects. Time was measured in weeks from the
initial visit. The initial pre-treatment visit was coded as
zero. Both linear and quadratic trends were examined
and goodness-of-fit tests of the deviance between linear
and quadratic models were used to assess most appropri-
ate fit. For all models examined, a linear model fit the
data better than a quadratic model (p< 0.05).Results
Sample characteristics
Thirty women with early-stage breast cancer were en-
rolled. Fifteen women received PBRT, Mammosite
brachytherapy at dose of 34 Gy 10 fractions/5 days,
while fifteen women received WBRT, 3-D conformal
techniques at dose of 50 Gy +10 Gy Boost/30 fractions.
Means, standard deviations and frequencies of partici-
pant demographic characteristics are listed in Table 1.
There were no significant differences between the
groups with regard to age (t(28) = 0.82, p = 0.42), marital
status, race, or adjuvant anti-estrogen endocrine therapy
use (χ2 = 0.05-1.87, p = 0.17-0.82).
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A longitudinal design was used to compare the effects of
WBRT versus PBRT on fatigue, perceived stress, quality of
life and NKCA in women with early stage breast cancer.
HLM analysis estimated trajectories of outcome variables
from the initial assessment prior to radiation therapy
through a projected 6-week period of time post radiation
therapy. Estimates of fixed and random effects for the final
models, including covariates, are presented in Table 2
(summary for all patients). The fixed effects capture sys-
tematic inter-individual differences in change trajectory
according to the values of the predictors, whereas random
effects represent estimated residual variance. Figures 1, 2,
3 and 4 illustrate the effects of the two types of radiation
therapy on the trajectories of study outcomes. The mean
scores for the outcome variables depicted in the figures
are estimated or predicted by the HLM results.
Fatigue
Fatigue was assessed by administering the FACT-F, in
which higher scores indicate less fatigue. Fatigue was sig-
nificantly associated with change over time, such that for
women who received PBRT, fatigue was estimated to de-
crease (b = 1.11, p= 0.04); in contrast, for women who
received WBRT, fatigue was estimated to increase
(b =−1.22, p= 0.04) with each additional week (Figure 1).
There were no group differences in the initial level of fa-
tigue (i.e., prior to initiation of radiation therapy)












Time x Group 1.11 (.56)*
Time x Age .04 (.04)
Time x Anti-Estrogen Therapy .40 (.83)
Variance Components
In intercept 116.89***
In linear slope 1.41**
Abbreviations: FACT-G = Functional Assessment of Cancer Therapy – General; FACT-
Scale, NKCA=Natural Killer Cell Activity.
aTime was coded 0 at the time of the diagnosis. *p< 0.05, **p< .01, ***p< 0.001.associated with reports of fatigue. There was a significant
amount of individual variation, as indicated by the vari-
ance components of the model, in the initial level of fa-
tigue (p< 0.0001), but not in the slope (p= 0.17). This
suggests that the type of radiation therapy that women
received was able to sufficiently explain the amount of
variance in the trajectories associated with each partici-
pant; however, additional factors (not assessed in the
present study) likely contributed to the unexplained vari-
ance at the initial status.
Perceived stress
No group differences in the initial level or the change in
the level of perceived stress were observed. As shown in
Table 2 and Figure 2, the level of perceived stress
remained relatively stable for both WBRT (b =−0.42,
p= 0.31) and PBRT (b =−0.10, p= 0.78). None of the
demographic variables were significantly associated with
perceived stress. Further, as indicated by the variance
components of the model, the type of radiation therapy
that women received, along with the covariate variables,
sufficiently accounted for the variance in the trajectories
associated with each participant (p= 0.27); although, at
baseline a significant amount of individual variation in
perceived stress remained unexplained.
Quality of life
The FACT–G total summary score was used to assess









48.1 (4.0)** 16.0 (2.9) 106.9 (38.7)
-1.22 (.56)* -.42 (.39) -5.00 (3.28)
4.62 (3.48) -.88 (2.50) -25.86 (33.52)
.14 (.22) -.22 (.16) 1.03 (2.14)
3.22 (3.39) -3.19 (3.18) -7.91 (45.95)
1.11 (.51)* -.10 (.35) 2.06 (3.04)
.04 (.03) .01 (.02) -.18 (.08)
.86 (.61) .10 (.44) 2.97 (3.08)
62.89*** 31.37*** 6514.53***
.48 .10 31.36**





















Figure 1 Influence of type of radiation therapy on trajectories of fatigue. Graphical representation of the relationship between type of
radiotherapy (WBRT=whole breast radiation therapy, PBRT = partial breast radiation therapy) and fatigue (FACT-F scores, score range 0–52) as
estimated by the hierarchical linear model. Note higher score indicates less fatigue from the time of the initial assessment (Baseline) to 6 weeks
post radiotherapy. Level of fatigue was similar for both groups at the initial assessment. Fatigue increased for women who received WBRT and
decreased for women who received PBRT over the 6 weeks post radiation therapy. *bslope x group = 1.11, p= 0.04.
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apy) of quality of life between women who received PBRT
or WBRT. However, the trajectories of change over the
post-treatment period were different for women who
received PBRT as compared to the WBRT group. As




















Figure 2 Influence of type of radiation therapy on trajectories of perc
type of radiotherapy (WBRT =whole breast radiation therapy, PBRT= partial
0–40) as estimated by the hierarchical linear model from the time of the in
differences were found with respect to the level of perceived stress at base
=0 .78 and 0.31.in quality of life was estimated for women receiving
PBRT (b = 1.11, p= 0.05), whereas quality of life slightly
decreased for women receiving WBRT (b=−0.74,
p=0.11). The effect of radiation therapy on the change over
time in quality of life remained statistically significant after
age and use of anti-estrogen endocrine therapy wereWBRT
PBRT
eived stress. Graphical representation of the relationship between
breast radiation therapy) and perceived stress (PSS scores, score range
itial assessment (Baseline) to 6 weeks post radiotherapy. No group






























Figure 3 Influence of type of radiation therapy on trajectories of quality of life. Graphical representation of the relationship between type
of radiotherapy (WBRT=whole breast radiation therapy, PBRT =partial breast radiation therapy) and quality of life (FACT-G scores, score range
0–108) as estimated by the hierarchical linear model from the time of the initial assessment (Baseline) to 6 weeks post radiotherapy. At the initial
assessment, groups did not differ with respect to quality of life. However, quality of life declined for women who received WBRT, whereas quality
of life increased for women who received PBRT over the 6 weeks post radiation therapy. *bslope x group = 1.11, p= 0.05.
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were significant predictors of either the intercept (i.e., ini-
tial level) nor the linear slope.
NKCA
No group differences (WBRT versus PBRT) were
observed in initial levels of NKCA or in the change in
NKCA over time. The demographic characteristics were
also not significant predictors of NKCA. Given the het-
erogeneity of NKCA, an additional model, as described
below, was evaluated to further explore the individual
change in NKCA over time post-treatment.
Additional analysis
For the following analysis, data for both groups
(WBRT and PBRT) were combined. The model investi-
gated fatigue and quality of life as predictors of the
change in NKCA (see Figure 4). Both predictor vari-
ables were treated as time-variant variables and were
entered simultaneously into the Level 1 model. Results
indicated that quality of life, but not fatigue, was sig-
nificantly associated with change in NKCA levels. For
those women who reported better quality of life, a
higher level of NKCA was estimated (b = 1.9, p= 0.02),
which remained elevated post treatment. Both random
effects components for the initial level and the linear
trend were significant (p< 0.001), suggesting that some
individual variability remained unexplained. One possi-
bility is that some portion of this variability was dueto the variance in blood collection times (i.e., 9 AM to
4 PM); however, this is unlikely because no correlation
was observed between time of blood draw and NKCA.Discussion
Novel modalities to administer radiation therapy for early
stage breast cancer have received increased attention.
Partial breast irradiation using brachytherapy delivers ra-
diation to a smaller volume of breast tissue by directing
radiation to the tissue adjacent to the excised lesion. Evi-
dence demonstrates that partial breast irradiation results
in excellent outcomes with respect to local tumor con-
trol, toxicity, and cosmesis at five year follow-up [1-4].
In contrast, a recent SEER database report suggested
that PBRT may be inferior to WBRT, with a doubling of
recurrence rates in women over 66 years of age [51].
However, this was a retrospective surrogate analysis of
insurance data. Moreover, the suitability of patient selec-
tion for breast brachytherapy (PBRT) has been called
into question [52-54], with one SEER study [54] showing
that 65% of women receiving PBRT fell in the unsuitable
cautionary group for PBRT based on the American Soci-
ety of Radiation Oncology guidelines. This may explain
the increased local recurrence reported by Smith et al.,
[55]. At this time, definitive conclusions regarding local
control and survival outcomes for PBRT must await
completion of an ongoing national study comparing





















Figure 4 Effect of quality of life on inter-individual differences in the intercept for NKCA. Graphical representation of the relationship
between quality of life (FACT-G scores) and natural killer cell activity (NKCA) as estimated by the hierarchical linear model from the time of the
initial assessment (i.e., Baseline) to 6 weeks post radiotherapy . The slopes for NKCA were based on differences in quality of life levels, calculated
as the average upper and lower quartiles. Greater levels of NKCA at baseline and post-treatment were associated with higher quality of life.
*bintercept = 1.9, p= 0.02.
Albuquerque et al. BMC Cancer 2012, 12:251 Page 8 of 12
http://www.biomedcentral.com/1471-2407/12/251PBRT may offer other advantages for women undergo-
ing adjuvant radiation therapy for breast cancer. Since
WBRT irradiates a greater volume of breast and normal
tissues than PBRT, it may lead to greater and more pro-
longed treatment-associated symptoms than PBRT. For
some women the longer duration of daily therapy ses-
sions can be physically and emotionally taxing and PBRT
may be better tolerated [14]. Our findings demonstrate
that women who receive PBRT, delivered for five days
with brachytherapy, exhibit a trajectory of decreasing fa-
tigue, compared to women receiving WBRT, who exhibit
worsening fatigue after radiation therapy. These results
are consistent with a recent retrospective study, which
showed that accelerated (3 weeks) partial breast irradi-
ation resulted in lower maximum fatigue during treat-
ment and lower severe fatigue at treatment completion
compared to conventional 6-week whole breast irradi-
ation [14]. Treatment modalities with lower associated
fatigue are clinically meaningful, as fatigue is one of the
most burdensome symptoms experienced by cancer
patients [7]. For most individuals receiving radiation
therapy, fatigue subsides to pre-treatment levels within
4–8 weeks after treatment completion [56-58]. Yet, for
some cancer survivors, fatigue can become a chronic
disabling condition, persisting for months or years after
successful cancer treatment [12].
A prior small study evaluated quality of life in women
receiving PBRT and showed improvements (change from
pre-surgical values) in emotional well being at 1 month
post-PBRT, which was followed months later by gains in
social/family well-being [43-45]. Yet that study did not
compare outcomes of quality of life for women receivingPBRT to that of women receiving WBRT, nor was fa-
tigue evaluated. Our results show baseline levels of qual-
ity of life to be good for both groups [59]. However, over
time post-radiation quality of life shows an increasing
trajectory in quality of life for women receiving PBRT,
but a decreasing trajectory of quality of life for women
receiving WBRT. Based on established criteria for what
is considered a minimally important difference (i.e., >5
point difference for the FACT-G total score), the differ-
ence in quality of life between these groups is considered
meaningful [60-62].
It is possible that the increasing trajectory in quality of
life we observed for women receiving PBRT may be
related to lower fatigue, as previous findings confirm
that cancer-related fatigue significantly interferes with
the course of daily living, diminishing quality of life
[10,63]. For women in the present study, baseline levels
of fatigue for both groups of women are within the range
of general population norms reported for the FACT-F
scale [64]. However, post-radiation we observe a de-
creasing trajectory of fatigue for women who received
PBRT, but an increasing trajectory for women who
received WBRT. By 6 weeks post-radiation, the lower fa-
tigue for women in the WBRT is at levels within the
range reported for non-anemic cancer patients [60]. Fur-
ther, the increasing difference in fatigue observed across
trajectories can be interpreted as meaningful, as the
minimal important difference for the FACT-F scale is
established to be in the range of 3–4 points [65,66]. A
shorter more focused course of radiation therapy that
results in lower fatigue and higher quality of life offers
clear advantage for women who are unable to tolerate
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treatment. This is an important consideration for elderly
women with breast cancer [67], as older age was demon-
strated to predict higher fatigue during radiation therapy
for breast cancer [14].
The underlying factors contributing to the differences
we observed in fatigue for women who received WBRT
versus those who received PBRT remain unclear. Psy-
chological factors are known to contribute to variation
in radiation-associated fatigue severity and duration
[15,68]. For women in the present study, perceived stress
scores are moderately elevated at baseline [23,48]. By 6-
weeks post-radiation, the perceived stress scores return
to levels similar to normative levels reported for women
without breast cancer [23]. However, we do not observe
differences in perceived stress based on type of radiation
therapy. Others show that depressive symptoms predict
higher fatigue trajectories for women with breast cancer
undergoing radiation therapy [15]. Although we did not
measure depressive symptoms, it is possible that women
receiving WBRT experience more depressive symptoms,
increasing risk for higher post-treatment fatigue.
Biological factors may underlie cancer-related fatigue
[22,69,70], in that circulating proinflammatory cytokines
can signal the brain and engender behavioral symptoms
like fatigue and depression [71,72]. Previous reports
demonstrate that women with breast cancer exhibit ele-
vated levels and/or production of proinflammatory cyto-
kines [9,23,24], with concomitant fatigue and depressive
symptoms [9,70,73,74]. Moreover, a quantitative meta-
analysis concluded that fatigue is associated with eleva-
tions in circulating levels of IL-6 in cancer patients [73].
Others identify inflammatory processes as potential med-
iators of radiation-induced fatigue in breast and prostate
cancer patients [22]. This may result from exposure to
radiation, which triggers inflammatory processes that
promote tissue repair [75,76]. WBRT may generate a
greater inflammatory response, resulting in more intense
and sustained fatigue and lower quality of life.
NK cells conduct immune surveillance against tumors
[27,29,32] and breast cancer is responsive to the anti-
tumor effects of NK cells [27,30-34]. Studies show that
higher NKCA predicts a better prognosis for cancer
patients [77-82]. As well, women with breast cancer who
report more behavioral symptom distress exhibit lower
NKCA [23-25], which may be mediated by elevations in
stress hormones [80,83-85]. Our results did not reveal
differences in NKCA based on type of breast radiation
therapy. This may be related to the lack of observed dif-
ferences in perceived stress between the two treatment
groups. However, post hoc analysis revealed that the per-
ception of better quality of life predicted higher NKCA,
post-treatment, for both groups of women (i.e., WBRT
and PBRT). We previously showed that a mindfulnessbased stress-reduction program for women undergoing
breast cancer treatment improved quality of life, as well
as reduced cortisol levels and increased NKCA restor-
ation after cancer treatment [24]. It is possible that the
perception of better quality of life during cancer treat-
ment, as observed in this study, may reduce endocrine
stress signals, resulting higher NKCA [69,85].Conclusions
In conclusion, these results show that PBRT resulted in
lower radiation-associated fatigue and higher quality of
life after radiation therapy compared to WBRT. Al-
though this pilot study is limited by the small sample
size and the non-randomization of subjects to treatment
group, the results identify advantages for choosing PBRT
for treatment of breast cancer. Women who begin radi-
ation therapy after adjuvant chemotherapy, women with
advanced age, and women with pre-existing co-morbidities
are patient subgroups at greater risk for radiation-
associated fatigue and poor quality of life; which can
interrupt cancer treatment and predispose to poor health
outcomes. Thus, these women may benefit from PBRT.
Moreover, the findings also demonstrate that better
quality of life predicted higher NKCA against tumor tar-
gets, emphasizing the importance of fostering good qual-
ity of life for women during radiation therapy. This is
clinically relevant, as after surgery and during adjuvant
treatment patients are at risk for post-surgical tumor
dissemination and NKCA is more effective in halting
nascent tumor cell seeding when tumor burden is low
[35,36,38]. Thus, the results of this investigation provide
evidence to assist clinical decision-making regarding
approaches for adjuvant radiation therapy after breast
conservation surgery.
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